From Financial Modeling Prep: 2025-05-13 14:00:00

PTC Therapeutics, Inc. (NASDAQ:PTCT) reported positive Phase 2 study results for PTC518, causing a stock price drop of 18.62%. Following this, Bronstein, Gewirtz & Grossman, LLC initiated an investigation for PTC investors. Citigroup upgraded PTC’s stock from Sell to Neutral, with a price target of $66, suggesting an 82.37% potential increase.

The Phase 2 PIVOT-HD study for PTC518 in Huntington’s disease showed promising results in reducing blood Huntingtin protein levels. Despite the stock price decline, analysts believe a Phase 3 study is needed for further confirmation. PTC’s stock price closed at $40.65 on May 5, 2025, after a $9.30 drop.

Citigroup upgraded PTC’s stock from Sell to Neutral on May 7, 2025, reflecting a more balanced outlook on the company’s future. Joel Beatty from Robert W. Baird set a price target of $66 for PTCT, indicating a potential 82.37% increase. Currently, PTC’s stock price is $46.05, with a trading volume of 493,831 shares.



Read more at Financial Modeling Prep:: PTC Therapeutics, Inc. (NASDAQ:PTCT) Faces Volatility Amid Clinical Study Results and Legal Investigation